-+ 0.00%
-+ 0.00%
-+ 0.00%

IPO News | Huayi Biotech's Hong Kong Stock IPO Prospectus Expires

Zhitongcaijing·05/22/2025 22:25:03
Listen to the news

The Zhitong Finance App learned that the Hong Kong Stock Prospectus submitted by Huayi Biotechnology (Qingdao) Co., Ltd. (abbreviation: Huayi Biotech) on November 22, 2024 expired on May 22, 2025 after 6 months. It submitted that Shihuatai International and CITIC Securities were co-sponsors.

image.png

According to the prospectus, Huayu Biotech is a biopharmaceutical company headquartered in China. It is committed to developing therapeutics, focusing on developing protein drugs for indications with medical needs and market opportunities. The company's main focus is to discover, develop, and commercialize wound healing therapies. Currently, it is a platelet-derived growth factor (“PDGF”) drug. PDGF is a growth factor secreted by platelets after damage, which stimulates cell proliferation and angiogenesis. The company's core products, Pro-101-1 and Pro-101-2, are recombinant human platelet-derived growth factor-BB (“rhPDGF-bB”) drugs. PDGFBB is one of the five dimer subtypes of PDGF, and rhPDGF-bb is the clinical application form of PDGF-bB. According to Frost & Sullivan's report, Pro-101-1 is the fastest progressing PDGF candidate for treating burns in China.